Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer.

Chu, Chia-Yu; Choi, Jennifer; Eaby-Sandy, Beth; Langer, Corey J; Lacouture, Mario E

Chu, Chia-Yu; Choi, Jennifer; Eaby-Sandy, Beth; Langer, Corey J; Lacouture, Mario E.

Afiliação

Chu CY; Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Choi J; Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Eaby-Sandy B; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Langer CJ; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Lacouture ME; Memorial Sloan Kettering Cancer Center, New York City, New York, USA lacoutum@mskcc.org.

Oncologist ; 23(8): 891-899, 2018 08.

Article em En | MEDLINE | ID: mdl-29650685

Assuntos

Acrilamidas/uso terapêutico; Compostos de Anilina/uso terapêutico; Antineoplásicos/uso terapêutico; Acrilamidas/farmacologia; Adulto; Idoso; Compostos de Anilina/farmacologia; Antineoplásicos/farmacologia; Feminino; Humanos; Masculino; Pessoa de Meia-Idade

Palavras-chave

Dermatologic adverse events; Epidermal growth factor receptor; Nonsmall cell lung cancer; T790M; Tyrosine kinase inhibitor

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Acrilamidas / Compostos de Anilina / Antineoplásicos Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google